At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 611 enrolled
Drug / intervention
GSK2340274A +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Safety and Immunogenicity of an A/California/7/2009 (H1N1)V-like Vaccine GSK2340274A or GSK2340273A Co-administered With Trivalent Inactivated Seasonal Influenza Vaccine in Adults 19 to 40 Years of Age
In Brief
A Phase 2 clinical trial evaluating GSK2340274A, GSK2340273A, and 2 other interventions for Influenza. Completed, enrolled 611 participants across 7 sites in 2 countries.
Detailed Summary
The purpose of this study is to characterize the safety and immunogenicity of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A when co-administered with the seasonal flu vaccine in adults 19 to 40 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionDec 2009
Study CompletionDec 2010
TodayJul 2026
First PostedSep 28, 2009
Enrollment StartOct 1, 2009
Primary CompletionDec 28, 2009
Study CompletionDec 29, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 16.8 years ago
Interventions
GSK2340274Abiological
Two intramuscular injections
GSK2340273Abiological
Two intramuscular injections
Seasonal trivalent influenza vaccine (TIV)biological
Single intramuscular injection
Saline placebobiological
Single intramuscular injection